G1 Ther­a­peu­tic­s' stock sinks near­ly 40% on PhI­II read­out de­lay

G1 Ther­a­peu­tics an­nounced that it will be con­tin­u­ing its Phase III breast can­cer tri­al for its drug Cosela fol­low­ing an in­ter­im analy­sis, push­ing back a da­ta read­out and send­ing its stock $GTHX down near­ly 40%.

The Phase III tri­al, called PRE­SERVE 2, was in­ves­ti­gat­ing tri­laci­clib, a CDK4/6 in­hibitor, in com­bi­na­tion with gem­c­itabine and car­bo­platin for the first-line treat­ment of metasta­t­ic triple neg­a­tive breast can­cer. The com­pa­ny had said it would share the re­sults at the in­ter­im analy­sis if it had achieved the pri­ma­ry end­point. Now, G1 says it won’t get a fi­nal analy­sis on the pri­ma­ry end­point un­til the third quar­ter of 2024.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER